Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients

Thrombosis Journal

Volumn 4, Issue , 2006, Pages

  McGarry, Lisa J ^a   Stokes, Michael E ^b   Thompson, David ^a  

^a Global Health Economics   (United States)

^b UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; HEPARIN;

ACUTE DISEASE; ADULT; AGED; ARTICLE; BLEEDING; COST BENEFIT ANALYSIS; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG COST; DRUG FATALITY; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HOSPITAL COST; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INCIDENCE; LENGTH OF STAY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RISK FACTOR; THROMBOSIS; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

EID: 33750944556     PISSN: 14779560     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/1477-9560-4-17     Document Type: Article

References (10)

1. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG: Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126(3 Suppl):338S-400S.
2. Tapson VF, Decousus H, Piovella F, Zotz RB, Allegrone J, Anderson FA: A multinational observational cohort study in acutely ill medical patients of practices in prevention of venous thromboembolism: findings of the international medical prevention registry on venous thromboembolism (IMPROVE). Blood 2003, 102(11):321a. (abstract)
3. Harenberg J, Kallenbach B, Martin U, Dempfle CE, Zimmermann R, Kubler W, Heene DL: Randomized controlled study of heparin and low-molecular weight heparin for prevention of deepvein thrombosis in medical patients. Thromb Res 1990, 59:639-50. DOI 10.1016/0049-3848(90)90422-9
4. Bergmann JF, Neuhart E: A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. Thromb and Haemost 1996, 76:529-34.
5. Harenberg J, Roebruck P, Heene DL: Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. Haemostasis 1996, 26:127-39.
6. Lechler E, Schramm W, Flosbach CW, THE PRIME study group: The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). Haemostasis 1996, 26(suppl 2):49-56.
7. Kleber FX, Witt C, Vogel G, Koppenhagen K, Schomaker U, Flosbach CW, THE-PRINCE Study Group: Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 2003, 145:614-21. DOI 10.1067/mhj.2003.189
8. United States Department of Health & Human Services Office for Civil Rights: HIPAA: Medical Privacy - National Standards to Protect the Privacy of Personal Health Information. http://www.hhs.gov/ocr/hipaa/ finalreg.html]. Accessed July 26, 2004
9. United States Department of Health & Human Services Centers for Medicare & Medicaid Service (CMS): CMS Files for Download for Medicare Payment Systems (formerly PUF Files). Prospective Payment System (PPS) - Payment Impact File 2001. [http://www.cms.hhs.gov /providers/pufdownload/ #impact]. Accessed June 23, 2002
10. Rubin DB: Estimating causal effects from large data sets using propensity scores, Ann Intern Med 1.